

*Response to Election of Species Requirement
U.S. Patent Application Serial No. 10/650,110
Page 2*

RECEIVED
CENTRAL FAX CENTER

MAY 14 2007

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

1-16 (Cancelled)

17. (New) A method for treating Alzheimer's disease in a patient diagnosed with the Alzheimer's disease, comprising administering to the patient an amount of a composition comprising a partially delipidated plasma having a lower content of at least one of triglycerides or cholesterol than a naturally occurring plasma, wherein the amount is effective to treat the Alzheimer's disease in the patient.

18. (New) The method of Claim 17, wherein the partially delipidated plasma has a lower content of triglycerides and cholesterol than the naturally occurring plasma.

19. (New) The method of Claim 17, wherein the partially delipidated plasma comprises a partially delipidated high density lipoprotein having a lower level of cholesterol than a high density lipoprotein in the naturally occurring plasma and a partially delipidated low density lipoprotein having a lower level of cholesterol than a low density lipoprotein in the naturally occurring plasma.

20. (New) The method of Claim 17, wherein the partially delipidated plasma is formed by a process comprising a step of exposing the naturally occurring plasma to a lipid removing agent.

21. (New) The method of Claim 20, wherein the lipid removing agent comprises an ether.

22. (New) The method of Claim 20, wherein the lipid removing agent comprises a combination of an alcohol and an ether.

23. (New) The method of Claim 17, wherein the method further comprises:

withdrawing blood containing blood cells from the patient;

US2000 9976065.1

*Response to Election of Species Requirement
U.S. Patent Application Serial No. 10/650,110
Page 3*

separating the blood cells from the blood to yield the naturally occurring plasma from the patient; and

exposing the naturally occurring plasma from the patient to a lipid removing agent to derive the partially delipidated plasma.

24. (New) The method of Claim 23, further comprising, a step of separating the partially delipidated plasma from the lipid removing agent before administering the partially delipidated plasma to the patient.

25. (New). The method of Claim 17, wherein the method reduces amyloid plaque, decreases neurofibrillary tangles, reduces levels of A β , alters a ratio of A β 40 to A β 42, affects enzymatic processing of APP, or reduces levels of phosphorylated tau protein, or a combination thereof, in the patient.

26. (New) The method of Claim 17, wherein the patient has increased blood cholesterol levels.

27. (New) The method of Claim 17, wherein the method reduces dementia in the patient.

28. (New) A method of delaying onset of symptoms of Alzheimer's disease in a patient at risk of developing the Alzheimer's disease, comprising administering to the patient an amount of a composition comprising a partially delipidated plasma having a lower content of at least one of triglycerides or cholesterol than a naturally occurring plasma, wherein the amount is effective to delay the onset of symptoms of the Alzheimer's disease in the patient.

29. (New) The method of Claim 28, wherein the partially delipidated plasma has a lower content of triglycerides and cholesterol than the naturally occurring plasma.

30. (New) The method of Claim 28, wherein the partially delipidated plasma comprises a partially delipidated high density lipoprotein having a lower level of cholesterol than a high density lipoprotein in the naturally occurring plasma and a partially delipidated low density lipoprotein having a lower level of cholesterol than a low density lipoprotein in the naturally occurring plasma.

US2008 9976065.1

*Response to Election of Species Requirement
U.S. Patent Application Serial No. 10/650,110
Page 4*

31. (New) The method of Claim 28, wherein the partially delipidated plasma is formed by a process comprising a step of exposing the naturally occurring plasma to a lipid removing agent.
32. (New) The method of Claim 28, wherein the lipid removing agent comprises an ether.
33. (New) The method of Claim 28, wherein the lipid removing agent comprises a combination of an alcohol and an ether.
34. (New) The method of Claim 28, wherein the method further comprises:
 - withdrawing blood containing blood cells from the patient;
 - separating blood cells from the blood to yield the naturally occurring plasma from the patient; and
 - exposing the naturally occurring plasma from the patient to a lipid removing agent to derive the partially delipidated plasma.
35. (New) The method of Claim 34, further comprising, a step of separating the partially delipidated plasma from the lipid removing agent before administering the partially delipidated plasma to the patient.
36. (New). The method of Claim 28, wherein the method reduces amyloid plaque, decreases neurofibrillary tangles, reduces levels of A β , alters a ratio of A β 40 to A β 42, affects enzymatic processing of APP, or reduces levels of phosphorylated tau protein, or a combination thereof, in the patient.
37. (New) The method of Claim 28, wherein the patient has increased blood cholesterol levels.
38. (New) The method of Claim 28, wherein the method delays onset of dementia in the patient.
39. (New) A method of treating or delaying onset of symptoms of Alzheimer's disease in a patient, comprising the steps of:

US20069976065.1

*Response to Election of Species Requirement
U.S. Patent Application Serial No. 10/650,110
Page 5*

withdrawing blood containing blood cells from the patient;
separating the blood cells from the blood to yield a naturally occurring plasma from the patient;
exposing the naturally occurring plasma from the patient to a lipid removing agent to derive a partially delipidated plasma having a lower content of at least one of triglycerides or cholesterol than the naturally occurring plasma;
separating the partially delipidated plasma from the lipid removing agent; and
administering to the patient an amount of a composition comprising the partially delipidated plasma, wherein the amount is effective to treat or delay onset of the symptoms of the Alzheimer's disease in the patient.